argenex (ARGX) News Today

argenex SE (NASDAQ:ARGX) moved higher and reached a new one-year high after positive Phase 3 clinical data and a series of analyst upgrades. The news strengthens expectations for continued growth of Vyvgart and potential expansion into autoimmune myositis.

• Positive Sentiment: argenx reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo met its primary endpoint in autoimmune myositis. The result supports a potential label expansion for the drug and was followed by a sharp increase in the shares. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo
• Positive Sentiment: Morgan Stanley said the myositis data strengthen the outlook for efgartigimod, the active ingredient in Vyvgart, and raised its price target for argenex SE from $1,200 to $1,230 while maintaining an “overweight” rating. Argenx's Myositis Data Strengthen Efgartigimod Outlook
• Positive Sentiment: Several firms lifted their targets after the trial update: Piper Sandler to $1,215, Wedbush to $1,150, RBC to $1,100, Truist to $1,095, HC Wainwright to $1,202 and Citizens JMP to $1,200. The upgrades generally retained bullish ratings, signaling greater expected upside and confidence in the commercial opportunity.
• Positive Sentiment: The analyst optimism helped ARGX hit a new 52-week high, with the stock opening near $993 versus a prior 52-week high of $1,009.75. argenex Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Investors will likely focus next on regulatory and commercialization milestones for the myositis indication. Although analyst targets imply further upside, ARGX already trades near its 52-week high, making execution and valuation important considerations.